(Q36724656)

15 August 2017

1 reference

title

Drug discovery for heart failure: a new era or the end of the pipeline? (English)

1 reference

15 August 2017

0 references

1 reference

2

Henry Krum

1 reference

15 August 2017

David M Kaye

1

1 reference

15 August 2017

publication date

1 February 2007

1 reference

Nature Reviews Drug Discovery

15 August 2017

published in

1 reference

15 August 2017

volume

6

1 reference

15 August 2017

issue

2

1 reference

15 August 2017

page(s)

127-139

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd2219

15 August 2017

exact match

0 references

cites work

Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation

1 reference

Aldosterone production is activated in failing ventricle in humans

21 January 2018

1 reference

Expression profiling of cardiovascular disease

21 January 2018

1 reference

Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril.

21 January 2018

1 reference

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

21 January 2018

1 reference

Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases

21 January 2018

1 reference

Polymorphisms of the beta(2)-adrenergic receptor determine exercise capacity in patients with heart failure

21 January 2018

1 reference

Recent advances in cardiac beta(2)-adrenergic signal transduction

21 January 2018

1 reference

Elevated Levels of 8-iso-Prostaglandin F 2α in Pericardial Fluid of Patients With Heart Failure

21 January 2018

1 reference

The polymorphonuclear leukocyte and the abdominal aortic aneurysm: a neglected cell type and a neglected disease

21 January 2018

1 reference

Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology.

31 March 2020

1 reference

Long-Term Trends in the Incidence of and Survival with Heart Failure

31 March 2020

1 reference

Trends in Heart Failure Incidence and Survival in a Community-Based Population

31 March 2020

1 reference

Prevalence of heart failure and left ventricular dysfunction in the general population; The Rotterdam Study

31 March 2020

1 reference

The heart failure epidemic: exactly how big is it?

31 March 2020

1 reference

Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population

31 March 2020

1 reference

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

31 March 2020

1 reference

Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD)

31 March 2020

1 reference

Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis

31 March 2020

1 reference

Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat

31 March 2020

1 reference

Angiotensin II type 1A receptor knockout mice display less left ventricular remodeling and improved survival after myocardial infarction

31 March 2020

1 reference

Persistent cardiac aldosterone synthesis in angiotensin II type 1A receptor-knockout mice after myocardial infarction

31 March 2020

1 reference

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

31 March 2020

1 reference

Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure

31 March 2020

1 reference

Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure

31 March 2020

1 reference

Overflow of catecholamine neurotransmitters to the circulation: source, fate, and functions

31 March 2020

1 reference

Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure.

31 March 2020

1 reference

Adverse consequences of high sympathetic nervous activity in the failing human heart

31 March 2020

1 reference

Antiadrenergic therapy of chronic heart failure: surprises and new opportunities

31 March 2020

1 reference

beta(2)-adrenergic receptor overexpression exacerbates development of heart failure after aortic stenosis

31 March 2020

1 reference

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group

31 March 2020

1 reference

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

31 March 2020

1 reference

Adverse mortality effect of central sympathetic inhibition with sustained‐release moxonidine in patients with heart failure (MOXCON)

31 March 2020

1 reference

RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study

31 March 2020

1 reference

Genomics, proteomics and bioinformatics of human heart failure

31 March 2020

1 reference

Controversies in ventricular remodelling

31 March 2020

1 reference

Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial.

31 March 2020

1 reference

Left Ventricular Remodeling and Ventricular Arrhythmias After Myocardial Infarction

31 March 2020

1 reference

Isolated myocyte contractile function is normal in postinfarct remodeled rat heart with systolic dysfunction

31 March 2020

1 reference

Cardiac hypertrophy: the good, the bad, and the ugly

31 March 2020

1 reference

Calcineurin inhibition and cardiac hypertrophy: a matter of balance

31 March 2020

1 reference

Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy

31 March 2020

1 reference

Dual roles of modulatory calcineurin-interacting protein 1 in cardiac hypertrophy

31 March 2020

1 reference

Inhibition of mTOR reduces chronic pressure-overload cardiac hypertrophy and fibrosis

31 March 2020

1 reference

Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding

31 March 2020

1 reference

The Rac and Rho hall of fame: a decade of hypertrophic signaling hits

31 March 2020

1 reference

Long-term inhibition of Rho-kinase suppresses left ventricular remodeling after myocardial infarction in mice

31 March 2020

1 reference

Physiological and pathological cardiac hypertrophy induce different molecular phenotypes in the rat.

31 March 2020

1 reference

Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study

31 March 2020

1 reference

Fibrosis as a therapeutic target post-myocardial infarction.

31 March 2020

1 reference

Beta-blocker improves survival, left ventricular function, and myocardial remodeling in hypertensive rats with diastolic heart failure

31 March 2020

1 reference

The cardiac fibroblast: therapeutic target in myocardial remodeling and failure

31 March 2020

1 reference

Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial

31 March 2020

1 reference

Tranilast attenuates cardiac matrix deposition in experimental diabetes: role of transforming growth factor-beta

31 March 2020

1 reference

p38 mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat

31 March 2020

1 reference

Inhibition of protein kinase C reduces left ventricular fibrosis and dysfunction following myocardial infarction

31 March 2020

1 reference

A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes

31 March 2020

1 reference

Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?

31 March 2020

1 reference

Accelerated LV remodeling after myocardial infarction in TIMP-1-deficient mice: effects of exogenous MMP inhibition

31 March 2020

1 reference

Inflammatory and anti-inflammatory cytokines in chronic heart failure: potential therapeutic implications

31 March 2020

1 reference

Inflammatory mediators and the failing heart: past, present, and the foreseeable future

31 March 2020

1 reference

Circulating levels of tumor necrosis factor correlate with indexes of depressed heart rate variability: a study in patients with mild-to-moderate heart failure

31 March 2020

1 reference

Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL).

31 March 2020

1 reference

Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure

31 March 2020

1 reference

Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy

31 March 2020

1 reference

Broad modulation of tissue responses (immune activation) by celacade may favorably influence pathologic processes associated with heart failure progression

31 March 2020

1 reference

Effects of a novel immune modulation therapy in patients with advanced chronic heart failure: results of a randomized, controlled, phase II trial

31 March 2020

1 reference

Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group

31 March 2020

1 reference

Intracellular calcium release and cardiac disease

31 March 2020

1 reference

Ryanodine receptor-targeted anti-arrhythmic therapy

31 March 2020

1 reference

Binding of levosimendan, a calcium sensitizer, to cardiac troponin C.

31 March 2020

1 reference

Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure

31 March 2020

1 reference

Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment

31 March 2020

1 reference

Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure

31 March 2020

1 reference

Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions

31 March 2020

1 reference

Xanthine oxidase inhibition and heart failure: novel therapeutic strategy for ventricular dysfunction?

31 March 2020

1 reference

Inhibition of copper-zinc superoxide dismutase induces cell growth, hypertrophic phenotype, and apoptosis in neonatal rat cardiac myocytes in vitro

31 March 2020

1 reference

Oxidative stress-mediated cardiac cell death is a major determinant of ventricular dysfunction and failure in dog dilated cardiomyopathy

31 March 2020

1 reference

Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure

31 March 2020

1 reference

Xanthine oxidoreductase inhibition causes reverse remodeling in rats with dilated cardiomyopathy

31 March 2020

1 reference

Statins and chronic heart failure: do we need a large-scale outcome trial?

31 March 2020

1 reference

Cholesterol and mortality in heart failure: the bad gone good?

31 March 2020

1 reference

The endotoxin-lipoprotein hypothesis

31 March 2020

1 reference

The effect of HMG-CoA reductase inhibitors on coenzyme Q10: possible biochemical/clinical implications

31 March 2020

1 reference

Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy

31 March 2020

1 reference

Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure

31 March 2020

1 reference

Structure-based design of aliskiren, a novel orally effective renin inhibitor

31 March 2020

1 reference

Therapeutic potential of renin inhibitors in the management of cardiovascular disorders

31 March 2020

1 reference

7-Chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): A potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist

31 March 2020

1 reference

Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial

31 March 2020

1 reference

Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial

31 March 2020

1 reference

Vasopressin antagonism in heart failure

31 March 2020

1 reference

Congestive heart failure and expression of myocardial urotensin II.

31 March 2020

1 reference

Differential effect of urotensin II on vascular tone in normal subjects and patients with chronic heart failure

31 March 2020

1 reference

Plasma urotensin II in heart failure

31 March 2020

1 reference

Aminoalkoxybenzyl pyrrolidines as novel human urotensin-II receptor antagonists

31 March 2020

1 reference

Urotensin II: its function in health and its role in disease.

31 March 2020

1 reference

Adrenomedullin and heart failure

31 March 2020

1 reference

Potent and long-lasting vasodilatory effects of adrenomedullin in humans. Comparisons between normal subjects and patients with chronic heart failure

31 March 2020

1 reference

Pathophysiologic and therapeutic implications of adrenomedullin in cardiovascular disorders

31 March 2020

1 reference

Effects of the renal natriuretic peptide urodilatin (ularitide) in patients with decompensated chronic heart failure: a double-blind, placebo-controlled, ascending-dose trial

31 March 2020

1 reference

Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure

31 March 2020

1 reference

Impact of diabetes mellitus on long-term survival in patients with congestive heart failure.

31 March 2020

1 reference

Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left V

31 March 2020

1 reference

Effects of BG9719 (CVT-124), an A1-adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure

31 March 2020

1 reference

Effects of adenosine receptor subtype A1 on ventricular and renal function

31 March 2020

1 reference

Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure

31 March 2020

1 reference

Clinical trials update from the American College of Cardiology: Darbepoetin alfa, ASTEROID, UNIVERSE, paediatric carvedilol, UNLOAD and ICELAND.

31 March 2020

1 reference

The phantom of lactic acidosis due to metformin in patients with diabetes

31 March 2020

1 reference

Improved clinical outcomes associated with metformin in patients with diabetes and heart failure

31 March 2020

1 reference

Reducing the costs of phase III cardiovascular clinical trials

31 March 2020

1 reference

Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE).

31 March 2020

1 reference

Gene therapy targeted at calcium handling as an approach to the treatment of heart failure

31 March 2020

1 reference

Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase in a rat model of heart failure

31 March 2020

1 reference

Cell therapy for heart failure--muscle, bone marrow, blood, and cardiac-derived stem cells

31 March 2020

1 reference

Beta-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure

31 March 2020

1 reference

A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor

31 March 2020

1 reference

A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure

31 March 2020

1 reference

Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties.

31 March 2020

1 reference

The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure

31 March 2020

1 reference

From mouse to man: understanding heart failure through genetically altered mouse models

31 March 2020

1 reference

Prevalence of heart failure and systolic ventricular dysfunction in older Australians: the Canberra Heart Study.

31 March 2020

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRD2219

1 reference

Dimensions Publication ID

15 August 2017

1044277847

0 references

Fatcat ID

release_g5u7wt5u2bbrlf37s4qp2hanim

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/g5u7wt5u2bbrlf37s4qp2hanim

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference